Rhythm Pharmaceuticals (RYTM) Scheduled to Post Earnings on Tuesday

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($2.12) per share for the quarter. Individual interested in listening to the company's earnings conference call can do so using this link.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Thursday, February 22nd. The company reported ($0.70) earnings per share for the quarter, meeting the consensus estimate of ($0.70). The firm had revenue of $24.23 million for the quarter, compared to analyst estimates of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative return on equity of 96.02%. The company's revenue for the quarter was up 175.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.75) earnings per share. On average, analysts expect Rhythm Pharmaceuticals to post $-4 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Rhythm Pharmaceuticals Stock Up 2.4 %

RYTM stock traded up $0.94 during trading hours on Tuesday, hitting $39.76. The company's stock had a trading volume of 628,635 shares, compared to its average volume of 617,400. The stock has a 50 day moving average price of $41.21 and a two-hundred day moving average price of $39.18. Rhythm Pharmaceuticals has a 12 month low of $15.50 and a 12 month high of $52.57. The company has a market capitalization of $2.39 billion, a PE ratio of -12.42 and a beta of 1.90.

Insiders Place Their Bets

In other news, EVP Yann Mazabraud sold 1,594 shares of the firm's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total value of $81,899.72. Following the sale, the executive vice president now directly owns 7,702 shares of the company's stock, valued at $395,728.76. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, EVP Yann Mazabraud sold 1,594 shares of the business's stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $51.38, for a total transaction of $81,899.72. Following the completion of the transaction, the executive vice president now owns 7,702 shares of the company's stock, valued at approximately $395,728.76. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Joseph Shulman sold 71,774 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $50.38, for a total value of $3,615,974.12. Following the sale, the insider now owns 2,686 shares of the company's stock, valued at approximately $135,320.68. The disclosure for this sale can be found here. Insiders sold a total of 172,069 shares of company stock valued at $7,626,355 in the last quarter. Insiders own 4.70% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on RYTM shares. Wells Fargo & Company decreased their price objective on shares of Rhythm Pharmaceuticals from $53.00 to $52.00 and set an "overweight" rating for the company in a report on Thursday, April 18th. Needham & Company LLC reissued a "buy" rating and set a $50.00 price objective on shares of Rhythm Pharmaceuticals in a report on Friday. Finally, The Goldman Sachs Group raised their price objective on Rhythm Pharmaceuticals from $42.00 to $52.00 and gave the company a "buy" rating in a research note on Thursday, January 25th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $47.20.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.